Putting chirality to work: The strategy of chiral switches

Nature Reviews Drug Discovery

Volumn 1, Issue 10, 2002, Pages 753-768

  Agranat, Israel ^a,b   Caner, Hava ^b   Caldwell, John ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BUPIVACAINE; CETIRIZINE; CISAPRIDE; CITALOPRAM; DEXFENFLURAMINE; DEXIBUPROFEN; DEXKETOPROFEN; DEXMETHYLPHENIDATE; ESCITALOPRAM; ESOMEPRAZOLE; FENFLURAMINE; FLURBIPROFEN; FORMOTEROL FUMARATE; IBUPROFEN; KETOPROFEN; LANSOPRAZOLE; LEVALBUTEROL; LEVOBUPIVACAINE; LEVOCETIRIZINE; LEVOFLOXACIN; METHYLPHENIDATE; OFLOXACIN; OMEPRAZOLE; OXYBUTYNIN; PANTOPRAZOLE; PONDOMIN; RABEPRAZOLE; SALBUTAMOL; UNINDEXED DRUG; ZOPICLONE;

AREA UNDER THE CURVE; BIOTECHNOLOGY; CHIRALITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG COST; DRUG DESIGN; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; ENANTIOMER; EXPIRATION DATE; PATENT; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; HUMAN; METHODOLOGY; PHARMACEUTICS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; STEREOISOMERISM; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036782116     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd915     Document Type: Review

References (146)

1. Eichelbaum, M. & Gross, A. S, Stereochemical aspects of drug action and disposition. Adv. Drug Res. 28, 1-64 (1996).
2. Crossley, R. Chirality and the Biological Activity of Drugs (CRC Press, Boca Raton, Florida, 1995).
3. Aboul-Enein, H. Y. & Wainer, I. W. (eds) The Impact of Stereochemistry on Drug Development and Use (Chemical Analysis Vol. 142) (Wiley, New York, 1997).
4. Triggle, D. J. Stereoselectivity of drug action. Drug Discov. Today 2, 138-147 (1997).
5. Caldwell, J. Through the looking glass in chiral drug development. Modern Drug Discov, 2, 51-60 (1999).
6. Challener, C. A. (ed.) Chiral Drugs (Ashgate, Burlington, Vermont, 2001).
7. Eichelbaum, M., Testa, B. & Somogyi, A. (eds) Stereochemical Aspects of Drug Action (Springer, Heidelberg, 2002).
8. Blumenstein, J. J. in Chirality in Industry II: Development in the Commercial Manufacture and Application of Optically Active Compounds (eds Collins, A. N., Sheldrake, G. N. & Crosby, J.) 11-18 (Wiley, New York, 1997).
9. Agranat, I. & Caner, H. Intellectual property and chirality of drugs. Drug Discov. Today 4, 313-321 (1999).
10. Rouhi, A. M. Chiral roundup. Chem. Eng. News 80, 43-50 (2002).
11. Stinson, S. C. Chiral chemistry. Chem. Eng. News 79, 45-56 (2001).
12. Tucker, G. T. Chiral switches. Lancet 355, 1085-1087 (2000).
13. Technology Catalyst International Corporation. Racemic Switch Update. World Market and Technology Assessment: Optically Active Chemical Compound Report 11th edn (Technology Catalyst International Corporation, Falls Church, Virginia, 2001).
14. Eliel, E. L., Wilen, S. H. & Mander, L. N. Stereochemistry of Organic Compounds (Wiley, New York, 1994).
15. Moss, G. P. Basic terminology of stereochemistry. Pure Appl. Chem. 68, 2193-2222 (1996).
16. Gardner, M. The Ambidextrous Universe: Symmetry and Asymmetry, From Mirror Reflections to Superstrips 3rd edn (W. H. Freeman and Company, New York, 1990).
17. Mislow, K. Molecular chirality. Top. Stereochem. 22, 1-82 (1999).
18. Bonner, W. A. Parity violation and the evolution of biomolecular homochirality. Chirality 12, 114-126 (2000).
19. Agranat, I. & Sarel, S. Introduction. Reflections on chiral discrimination. Enantiomer 1, 249-250 (1996).
20. Ariens, E. J. Stereochemistry: a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26, 663-668 (1984).
21. Caldwell, J. & Leonard, B. E. The enantiomer debate: realising the potential of enantiomers in pharmacology. Hum. Psychopharmacol. Clin. Exp. 16 (Suppl. 2), S65-S107 (2001).
22. Shah, R. R., Midgley J. M. & Branch, S. K. Stereochemical origin of some clinically significant drug safety concerns: lessons for future drug development. Adv. Drug React. Toxicol. Rev. 17, 145-190 (1998).
23. Bristol, J. A. & Doherty, A. M. (eds) To Market, To Market in Annual Reports in Medicinal Chemistry Vols 25-36 (Academic Press, San Diego, California, 1990-2001).
24. Miller, S. P. FDA perspectives on quality control for chiral pharmaceuticals. 13th Int. Symp. Chiral Discrimination Abstract L/316 and lecture (2001).
25. Branch, S. K. in Chiral Separation Techniques. A Practical Approach 2nd edn (ed. Subramaninn, G.) 317-341 (Wiley-VCH, Weinheim, 2000).
26. Branch, S. K. Regulatory issues and validation in chiral analysis. The Chiral Technology Conference 2000, CPI Worldwide, Milano (2000).
27. Lloyd, A. W. Stereochemistry: handling interactions. Drug Discov. Today 2, 127 (1997).
28. Gal, J. & Agranat, I. Comments Submitted to the US Food and Drug Administration (FDA) in response to FDA Notice on Policy Period of Marketing Exclusivity for Newly Approved Drug Products With Enantiomer Active Ingredients 62 Fed. Reg. 2167 FDA Dkt No. 97N-0002, Comment No. 7327 (1997).
29. Handley, D. A. The therapeutic advantages achieved through single-isomer drugs. Pharm. News 6, 11-15 (1999).
30. Cannarsa, M. J. Racemic switches: historical perspectives and current status. Chem. Oggi/Chem. Today 17, 28-32 (1999).
31. Food and Drug Administration. FDA's policy statement for the development of new stereoisomeric drugs. US Food and Drug Administration [online] (cited 26 Aug 2002) 57 Fed. Reg. 22, 249 (1992).
32. Committee for Proprietary Medicinal Products. Working Parties on Quality, Safety and Efficacy of Medicinal Products. Note for Guidance: Investigation of Chiral Active Substances, III/3501/91 (1993).
33. Daniels, J. M., Nestmann, E. R. & Kerr, A. Development of stereoisomeric (chiral) drugs: a brief review of scientific and regulatory considerations. Drug Inf. J. 31, 639-646 (1997).
34. Strong, M. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer more effective drugs. Food Drug Law J. 54, 463-487 (1999).
35. Department of Health and Human Services. The International Conference on Harmonization; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. US Food and Drug Administration (2000).
36. 54 Fed. Reg. At 28,898; 59 Fed. Reg. At 50,359.
37. US Food and Drug Administration. FDA Staff Manual Guide 4820.3. Drug Classification and Priority Review Policy (US Food and Drug Administration, 1992).
38. 21 USC §355(j)(5)(D) ii (1997).
39. 21 USC §355(j)(5)(D) iii (1997).
40. Carlson, S. C. The case against market exclusivity for purified enantiomers of approved drugs. Yale Symp. Law Technol. Vol. 6 (1999).
41. Grubb, P. W. Patents for Chemicals, Pharmaceuticals and Biotechnology (Oxford Univ. Press, Oxford, 1999).
42. Bainbridge, D. I. Intellectual Property 2nd edn (Pitman, London, 1994).
43. Patent and Trademark Laws (The Bureau of National Affairs, Washington DC, 1989).
44. European Patent Convention (European Patent Office, Munich, Germany, 1977).
45. Blanco White, T. A. Patents for Inventions 5th edn (Stevens & Sons, London, 1983).
46. I. G. Farhenindustrie. [1930] 47 RPC 289-341 (1930).
47. Bayer (Boatz). [1982] RPC 319-324 (EPO/TBA) (1982).
48. duPont (Witsipe). [1982] FRS 303-310 (H.L.) (1982).
49. Nayler, J. H. C. & Long, A. A. W. P-hydroxyampicillin and salts thereof. GB Patent 1,214,844 (1972).
50. Nayler, J. H. C. & Simth, H. Penicillins. GB Patent 978,178 (1964).
51. Beacham Group Limited's (Amoxicillin) Application (Court of Appeal). RPC 261-304 (1980).
52. Gray, N. M. & Young, J. W. Methods of using (+)-cisapride for the treatment of gastro-esophageal reflux disease and other disorders. EP Application 93918155.3 (1994).
53. Gray, N. M. & Young, J. W. Methods of using (-)-cisapride for the treatment of gastro-esophageal reflux disease and other disorders. EP Application 93916996.7 (1994).
54. Cisapride litigation: EPO Patent Application 93918153.3 ((+)-cisapride), EPO Application 93916996.7 ((-)-cisapride) (12 Aug 1997).
55. Hoogerwerf, W. A. & Pastricha, P. J. in Goodman and Gilman's The Pharmacological Basis of Therapeutics 10th edn (eds Hardman, J. G., Limbird, L. E. & Gilman, A. G.) 1005-1029 (McGraw Hill, New York, 2002).
56. Wong, P. Gastrointestinal Disorders: New Therapies for the New Millenium (PJB Publications, New York, 2000).
57. Graul, A., Castaner, R. & Castaner, J. Esomeprazole magnesium. Drugs Future 24, 1178-1183 (1999).
58. Spenser, C. M. & Faulds, D. Esomeprazole. Drugs 60, 321-329 (2000).
59. Carlsson, E., Lindberg, P. & von Unge, S. Two of a kind. Chem. Brit. 42-45 (May 2002).
60. Renfrey, S. & Featherstone, J. Structural proteomics. Nature Rev. Drug Discov. 1, 175-176 (2002).
61. Lindberg, P. et al. Omeprazole: the first proton pump inhibitor. Med. Res. Rev. 10, 1-60 (1990).
62. +)-ATPase inhibiting 2-(2-pyridylmethyl-sulphinyl)benzimidazoles: isolation and characterisation of the thiophilic 'active principle' and its reactions. J. Chem. Soc. Chem. Commun. 125-127 (1986).
63. Anonymous. US Prilosec patent trial drawing to close. SCRIP 2743, 17 (May 03, 2002).
64. Kale-Pradhan, P. B., Landry, H. K. & Sypula, W. T. Esomeprazole for acid peptic disorders. Ann. Pharmacother. 36, 655-663 (2002).
65. Center for Drug Evaluation and Research. Nexium delayed-release capsules: printed labeling. Center for Drug Evaluation and Research [online] (cited 26 Aug 2002) http://www.fda.gov/cder/foi/nda/2001/21154_nexium.htm (2001).
66. Lindberg, P. & Weidoff, L. Method for the treatment of gastric acid-related diseases and production of medication using (-)-enantiomer of omeprazole. US Patent 5,877,192 (1999).
67. Lindberg, P. & von Unge, S. Compositions. US Patent 5,714,504 (1998).
68. Graham, D., Holt, R., Taylor, S. & Lindberg, P. Method for preparing a pharmaceutically active enantiomeric or enantiomerically enriched sulfoxide compound by enantioselective bioreduction of a racemate sulfoxide compound. US Patent 5,776,765 (1998).
69. von Unge, S. Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole. US Patent 5,693,818 (1997).
70. Kronstroem, A., Moeller, E., Cotton, H. & Mattson, A. Form of S-omeprazole. WO Patent 98/54171 (1998).
71. Erlandsson P., Isaksson, R., Lorentzon, P. & Lindberg, P. Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase; the effect of the enantiomers of omeprazole on gastric glands. J. Chromatogr. B 532, 305-319 (1990).
72. Kohl, B. D. & Senn-Bilfinger, J. D. Enantiomerentrennung. DE Patent 4,035,455 (1992).
73. Jenkins, D. J., Sancilio, F. D., Stowell, G. W., Whittall, L. B. & Whittle, R. R. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same. US Patent 6,262,085 (2001).
74. Fontana, S. A. et al. Pharmaceutical unit dosage form. US Patent 6,262,086 (2001).
75. Fontana, S. A. et al. Dry blend pharmaceutical formulations. US Patent 6,268,385 (2001).
76. Jenkins, D. J., Sancilio, F. D., Stowell, G. W., Whittall, L. B. & Whittle, R. R. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same. US Patent 6,369,087 (2002).
77. Jenkins, D. J. et al. Method of improving bioavailability. US Patent 6,312,712 (2001).
78. Fontana, S. A. et al. Pharmaceutical unit dosage form. US Patent 6,312,723 (2001).
79. Jenkins, D. J. et al. Pharmaceutical formulations. US Patent 6,316,020 (2001).
80. Fontana, S. A. et al. Dry blend pharmaceutical unit dosage form. US Patent 6,326,384 (2001).
81. Caner, H. & Agranat, I. Poster 170. 6th World Congress of Theoretically Oriented Chemists (WATOC 2002), Lugano (2002).
82. Department of Health and Human Services. Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations 22nd edn. US Food and Drug Administration [online] (cited 26 Aug 2002) (2002).
83. Handley, D. A., Morely, J. & Vaickus, L. Levalbuterol hydrochloride. Expert Opin. Inv. Drugs 7, 2027-2042 (1998).
84. Gristwood, R. W. Cardiac and CNS toxicity of levobupivacaine: strength of evidence for advantage over bupivacaine. Drugs Saf. 25, 153-163 (2002).
85. Gristwood, R. W. & Greaves, J. L. Levobupivacaine: a new safer long acting local anaesthetic agent. Expert Opin. Inv. Drugs 8, 861-876 (1999).
86. Hutt, A. J. & Caldwell, J. The metabolic chiral inversion pf 2-arylpropionic acids - a novel route with pharmacological consequences. J. Pharm. Pharmacol. 35, 693-704 (1983).
87. Mayer, J. M. & Testa, B. Pharmacodynamics pharmacokinetics and toxicology of ibuprofen enantiomers. Drugs Future 22, 1347-1366 (1997).
88. S(+)-Ibuprofen/STERLING EPO/TBA. T 0315/98-3.3.2 (1999).
89. Barbanoj, M. J., Antonijoan, R. M. & Gich, I. Clinical pharmacokinetics of Dexketoprofen. Clin. Pharmacokinet. 40, 245-262 (2001).
90. Fishman, A. P. Aminorex to Fen/Phen: an epidemic foretold. Circulation 99, 156-161 (1999).
91. US Department of Health and Human Service. Cardiac valvulatory associated with exposure to fenfluramine or dexfenfluramine. US Department of Health and Human Service Interim Public Health Recommendations, November 1997. Morbid. Mortal. Weekly Rep. 46, 1061-1066 (1997).
92. Nicolaidis, S. (ed.) Obesity Management of Redux™ (Academic, San Diego, California, 1997).
93. Wurtman, R. J. & Wurtman, J. J. D-Fenfluramine for modifying feeding behavior. US Patent 4,309,445 (1982).
94. Wurtman, R. J. & Wurtman, J. J. Method of utilizing D,L-fenfluramine for modifying feeding behavior. US Patent 4,452,815 (1984).
95. Public Law 98-417. Drug Price Competition and Patent Term Restoration Act: Amendment of the Federal Food, Drug and Cosmetic Act (Hatch-Waxman Amendment) (1984).
96. Anonymous. Redux slated for US patent extension. SCRIP 2191, 19 (1996).
97. Weintraub, M., Hasday, J. D., Mushlin, A. L. & Lockwood, D. H. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144, 1143-1146 (1984).
98. Weintraub, M. et al. Long-term weight control study. Clin. Pharmacol. Ther. 51, 581-646 (1992).
99. Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
100. Abenhaim, L. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 335, 609-616 (1996).
101. Wong, D. T, Horng, J. S., Bymastee, K. P., Hauser, K. L. & Molloy, B. B. A selective inhibition of serotonin uptake: Lilly 11040, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 15, 471-479 (1974).
102. Baldessarin, R. J. in Goodman and Gilman's The Pharmacological Basis of Therapeutics 10th edn (eds Hardman, J. G., Limbird, L. E. & Gilman, A. G.) 447-483 (McGraw Hill, New York, 2002 ).
103. Robertson, D. W., Krushinski, J. H., Fuller, R, W. & Leander, J. D. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J. Med. Chem. 31, 1412-1417 (1998).
104. Young, J. W. & Barberich, T. J. Method for treating migraine headaches using optically pure S-(+)-fluoxetine. US patent 5,589,511 (1996).
105. Young, J. W., Barberich, T. J. & Teicher, M. H. Methods for treating depression and other disorders using optically pure R-(-)-fluoxetine and monoamine oxidase inhibitor. US patent 5,648,396 (1997).
106. Fuller, R. W., Robertson, D. W. & Wong, D. T. (S)-Norfluoxetine in method of inhibiting serotonin uptake. US patent 5,250,571 (1993).
107. Robertson, D. W. & Wong, D. T. (R)-Norfluoxetine in method for occupying serotonin IC receptors. US patent 5,250,572 (1993).
108. Anonymous. Lilly Sepracor deal on R-fluoxetine. SCRIP 2395, 8 (1998).
109. Schmiegel, K. K. & Molloy, B. B. Treatment of obesity with aryloxyphenylpropylamines. US patent 4,626,549 (1986).
110. Schmiegel, K. K. & Molloy, B. B. Aryloxyphenylpropylamines in treating depression. US patent 4,018,895 (1977).
111. US Court of Appeals Federal Circuit, 99-1262-1263-1265-1303. Eli Lilly and Company versus Barr Laboratories and others. First judgement dated 09 Aug 2000. Validated judgement dated 30 May 2001.
112. Schmiegel, K. K. & Molloy, B. B. Arloxyphenylpropylamines. US patent 4,314,081 (1982).
113. Stark, P. Anti-anxiety method. US patent 4,590,213 (1986).
114. US Food and Drug Administration. Modernization Act 1997 Pub. L No. 105-115 (1997).
115. Rogers, R. S. Sepracor: skating on 'ICE'. Chem. Eng. News 76, 11-13 (1998).
116. Tracy, J. W. & Webster, L. T. in Goodman and Gilman's The Pharmacological Basis of Therapeutics 10th edn (Hardman, J. G., Umbird, L. E. & Gilman, A. G.) 1059-1095 (McGraw Hill, New York, 2002).
117. Woodward, R. B. et al. The total synthesis of strychnine. Tetrahedron 19, 247-288 (1963).
118. Roden, D. in Goodman and Gilman's The Pharmacological Basis of Therapeutics 10th edn (Hardman, J. G., Limbird, L. E. & Gilman, A. G.) 933-970 (McGraw Hill, New York, 2002).
119. Jaroszewski, J. W., Stromhansen, T., Honorehansen, S., Thastrup, O. & Kofod, H. On the botanical distribution of chiral forms of gossypol. Planta Med. 58, 454-458 (1992).
120. Matlin, S. A. Prospects for pharmacological male contraception. Drugs 48, 851-863 (1994).
121. 23Na NMR Study. Nucl. Magnet. Reson. Biomed. 9, 72-78 (1996).
122. Liu, S. L. et al. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res. 22 (Suppl. 1A), 33-38 (2002).
123. Teerhuis, N. M., Huisman, I. A. M. & Groen, M. B. Synthesis of ent-19-nortestosterone from its naturally occuring antipode. Tetrahedron Lett. 42, 2869-2871 (2001).
124. A receptors. Brain Res. Rev. 37, 91-97 (2001).
125. Shohami, E. & Mechulam, R. Dexanabinol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev. Res. 50, 211-215 (2000).
126. Knoller, N. et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, Phase II clinical trial. Crit. Care Med. 30, 548-554 (2002).
127. Department of Health and Human Services. Lexapro approval letter. US Food and Drug Administration [online] (cited 26 Aug 2002) (2002).
128. Toft, A. S. & Bogeso, K. P. Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans. US Patent 4,136,193 (1979).
129. Toft, A. S. & Bogeso, K. P. Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans. GB Patent 1,526,331 (1979).
130. De Ranter, C. J. in X-Ray Crystallography and Drug Action (eds Horn, A. S. & De Ranter, C. J.) 3-4 (Clarendon, Oxford, 1984).
131. Ahlberg, P. The Nobel Prize in Chemistry 2001 -presentation speech. The Royal Swedish Academy of Science [online] (cited 26 Aug 2002) http//:www.nobel.se/chemistry/laureates/2001/presentation-speech.html (2001).
132. Blaschke, G., Kraft, H. P., Fickentscher, K. & Kohler, F. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschung 29, 1640-1642 (1979).
133. Fabro, S., Smith, R. L. & Williams, R. T. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215, 296-297 (1967).
134. Reist, M., Carrupt, P. A., Francotte, E. & Testa, B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11, 1521-1528 (1998).
135. Eriksson, T., Bjorkman, S., Roth, B., Fyge, A. & Hoglund, P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7, 44-52 (1995).
136. Re: May and Eddy. US Court of Customs and Patent Appeals. US CCPA 574F.2d1082, 197 USPQ 601 (1978).
137. Eli Lilly and Company versus Generix Drug Sales Inc. et al. 460F. 2nd 1096, US Court of Appeals for the Fifth Circuit. 174 USPQ (BNA) 65 (1972).
138. Enantiomers/HOECHST. European Technical Board of Appeals Decision. T 296/87 - 3.3.1 (1988).
139. SEPRACOR. European Technical Board of Appeals Decision. T 1031/00 - 3.3.2 (2002).
140. Gray, N. M. & Young, J. W. Methods of using (+)-cisapride for the treatment of gastro-esophageal reflux disease and other disorders. WO Patent 94/01111 (1994).
141. Gray, N. M. & Young, J. W. Methods of using (-)-cisapride for the treatment of gastro-esophageal reflux disease and other disorders. WO Patent 94/01112 (1994).
142. Norby, S. R. Levofloxacin. Expert Opin. Pharmacother. 1, 109-120 (1999).
143. Clough, G. F., Boutsiouki, P. & Church, M. K. Comparison of the effects of Levocetirizine and Loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 56, 985-988 (2001).
144. US Department of Health and Services. Approval Package. Focalin (dexmethylphenidate HCI) tablets. Company: Celgene. App. No. 21-278 (2001).
145. Baumann, P. & Eap, C. B. Enantiomeric antidepressant drugs should be considered on individual merit. Hum. Psychopharmacol. Clin. Exp. 16, S85-S92 (2001).
146. Braestrup, C. in Optimising the Treatment of Mood and Anxiety Disorders 13-17 (Lundbeck, Copenhagen, 2002).